ESMO2016 Eye on ESMO: Day 2 - gamechangers take centre stage Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise
ESMO2016 Eye on ESMO: Day 1 - Access in spotlight before data deluge Europe's biggest cancer conference ESMO is underway
Partner Content Partner Content On Demand: The Top 5 Challenges in Immuno-Oncology Trials In the battle against cancer, immunotherapy is proving to be one of the most promising avenues of research.
Articles A breakthrough in lung cancer - the biggest prize in immunot... AstraZeneca/MedImmune hopes its immunotherapy combinations will help it catch up with leaders.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.